These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 35211173)

  • 1. Pan-Cancer Analysis of Microfibrillar-Associated Protein 2 (MFAP2) Based on Bioinformatics and qPCR Verification.
    Qiu Z; Xin M; Wang C; Zhu Y; Kong Q; Liu Z
    J Oncol; 2022; 2022():8423173. PubMed ID: 35211173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
    Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
    Front Genet; 2022; 13():993438. PubMed ID: 36685895
    [No Abstract]   [Full Text] [Related]  

  • 3. A pan-cancer analysis to determine the prognostic analysis and immune infiltration of HSPA5.
    Zhu RK; Zhang W; Zhang YX; Hui Z; Wang XW
    Curr Cancer Drug Targets; 2023 May; ():. PubMed ID: 37157205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-Cancer Analysis Reveals the Multidimensional Expression and Prognostic and Immunologic Roles of
    Zhang S; Xiong H; Yang J; Yuan X
    Front Mol Biosci; 2021; 8():792154. PubMed ID: 35155565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potent potential of MFAP2 in prognosis and immunotherapy of triple-negative breast cancer.
    Huang J; Xu Y; Qi S; Zheng Q; Cui C; Liu L; Liu F
    Discov Oncol; 2024 Jun; 15(1):202. PubMed ID: 38822944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NALCN is a potential biomarker and therapeutic target in human cancers.
    He J; Xu J; Chang Z; Yan J; Zhang L; Qin Y
    Front Genet; 2023; 14():1164707. PubMed ID: 37152978
    [No Abstract]   [Full Text] [Related]  

  • 7. The use of MFAP2 for diagnosis, prognosis and immunotherapy of triple-negative breast cancer.
    Yu J; Wang F; Dong R; Jia W
    Am J Transl Res; 2024; 16(4):1322-1336. PubMed ID: 38715831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
    Zhang J; Wang K; Hainisayimu T; Li H
    Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-Cancer Analysis Revealed
    Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J
    J Oncol; 2022; 2022():3477148. PubMed ID: 35069733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of microfibrillar-associated protein 2 is closely associated with tumor angiogenesis and poor prognosis in hepatocellular carcinoma.
    Zhang N; Shao F; Jia W
    Oncol Lett; 2021 Oct; 22(4):739. PubMed ID: 34466151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic Analysis of the Oncogenic Role of WDR62 in Human Tumors.
    Bu Y; Zhang L; Ma X; Wang R; Zhang X; Li J
    Dis Markers; 2021; 2021():9940274. PubMed ID: 34306258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy.
    Hu J; Qiu D; Yu A; Hu J; Deng H; Li H; Yi Z; Chen J; Zu X
    Front Oncol; 2021; 11():607224. PubMed ID: 34026603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-Cancer Analysis Identified CD93 as a Valuable Biomarker for Predicting Patient Prognosis and Immunotherapy Response.
    Tong W; Wang G; Zhu L; Bai Y; Liu Z; Yang L; Wu H; Cui T; Zhang Y
    Front Mol Biosci; 2021; 8():793445. PubMed ID: 35265666
    [No Abstract]   [Full Text] [Related]  

  • 14. Pan-cancer analysis reveals IGFL2 as a potential target for cancer prognosis and immunotherapy.
    Wang Y; Yuan H; Yue G; Zhao L; Xia Y; Zhang N; Li H; Liu D; Su Y; Wang H; Gao Y
    Sci Rep; 2023 Apr; 13(1):6034. PubMed ID: 37055418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of NCS1 in Immunotherapy and Prognosis of Human Cancer.
    Wang GC; Gan X; Zeng YQ; Chen X; Kang H; Huang SW; Hu WH
    Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and Immunological Significance of ANKRD52 in Pan-Cancer.
    Yin HZ; Zhang MC; Wu H
    Biochem Genet; 2024 Dec; 62(6):4335-4358. PubMed ID: 38296907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. System Analysis of Adaptor-Related Protein Complex 1 Subunit Mu 2 (AP1M2) on Malignant Tumors: A Pan-Cancer Analysis.
    Yi Y; Zhang Q; Shen Y; Gao Y; Fan X; Chen S; Ye X; Xu J
    J Oncol; 2022; 2022():7945077. PubMed ID: 35154321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer.
    Chen G; Luo D; Zhong N; Li D; Zheng J; Liao H; Li Z; Lin X; Chen Q; Zhang C; Lu Y; Chan YT; Ren Q; Wang N; Feng Y
    Front Immunol; 2022; 13():857308. PubMed ID: 35345673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Implication and Oncogenic Role of PNPO in Pan-Cancer.
    Zhang L; Li X; Zhang J; Xu G
    Front Cell Dev Biol; 2021; 9():763674. PubMed ID: 35127701
    [No Abstract]   [Full Text] [Related]  

  • 20. Systematic pan-cancer analysis identifies
    Chen P; Yang X; Wang P; He H; Chen Y; Yu L; Fang H; Wang F; Huang Z
    Ann Transl Med; 2023 Jan; 11(2):121. PubMed ID: 36819495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.